Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Olema Pharmaceuticals ( (OLMA) ) just unveiled an announcement.
On August 11, 2025, Olema Pharmaceuticals reported its second quarter 2025 financial and operating results, highlighting the selection of a 90 mg dose of palazestrant for its OPERA-01 and OPERA-02 Phase 3 trials. The company is progressing with its clinical trials, expecting top-line data for OPERA-01 in the second half of 2026 and initiating OPERA-02 in Q3 2025. Olema ended the quarter with $361.9 million in cash and equivalents, despite a net loss of $43.8 million due to increased R&D spending and a milestone payment to Aurigene. The company’s focus on palazestrant and OP-3136 underscores its commitment to advancing breast cancer treatments.
The most recent analyst rating on (OLMA) stock is a Buy with a $29.00 price target. To see the full list of analyst forecasts on Olema Pharmaceuticals stock, see the OLMA Stock Forecast page.
Spark’s Take on OLMA Stock
According to Spark, TipRanks’ AI Analyst, OLMA is a Neutral.
Olema Pharmaceuticals faces substantial financial challenges with zero revenue and increasing losses, necessitating external funding. The technical analysis indicates some recent positive momentum, but the stock remains speculative due to negative profitability. The strategic collaboration with Novartis offers a positive outlook, potentially enhancing market position and supporting long-term growth. These factors collectively result in a moderate overall stock score.
To see Spark’s full report on OLMA stock, click here.
More about Olema Pharmaceuticals
Olema Oncology is a clinical-stage biopharmaceutical company focused on developing targeted therapies for breast cancer and beyond. The company is advancing a pipeline of novel therapies, including palazestrant (OP-1250), an estrogen receptor antagonist and degrader, and OP-3136, a KAT6 inhibitor, with operations in San Francisco and Cambridge, Massachusetts.
Average Trading Volume: 689,481
Technical Sentiment Signal: Sell
Current Market Cap: $317.5M
Learn more about OLMA stock on TipRanks’ Stock Analysis page.